StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bristol-Myers Squibb (BMY) Reports Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial
September 5, 2019 7:00 AM
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
September 5, 2019 6:59 AM
Bristol-Myers Squibb Co. (BMY) PT Raised to $49 at BofA/Merrill Lynch
September 3, 2019 8:37 AM